{"nctId":"NCT00680745","briefTitle":"Efficacy and Safety of Dapagliflozin in Combination With Glimepiride (a Sulphonylurea) in Type 2 Diabetes Patients","startDateStruct":{"date":"2008-04"},"conditions":["Type 2 Diabetes"],"count":597,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: dapagliflozin","Drug: Glimepiride","Drug: metformin hydrochloride","Drug: pioglitazone hydrochloride","Drug: Rosiglitazone"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: dapagliflozin","Drug: Glimepiride","Drug: metformin hydrochloride","Drug: pioglitazone hydrochloride","Drug: Rosiglitazone"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: dapagliflozin","Drug: Glimepiride","Drug: metformin hydrochloride","Drug: pioglitazone hydrochloride","Drug: Rosiglitazone"]},{"label":"4","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Glimepiride","Drug: metformin hydrochloride","Drug: pioglitazone hydrochloride","Drug: Rosiglitazone"]}],"interventions":[{"name":"dapagliflozin","otherNames":[]},{"name":"Glimepiride","otherNames":["Amaryl"]},{"name":"metformin hydrochloride","otherNames":["Glucophage"]},{"name":"pioglitazone hydrochloride","otherNames":["Actos"]},{"name":"Rosiglitazone","otherNames":["Avandia"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 Diabetes\n* Treatment with a stable sulphonylurea monotherapy dose that is at least half the maximal recommended dose for a minimum of 8 weeks prior to study\n* Inadequate glycaemic control, defined as A1C ≥ 7.0 % and ≤ 10%\n\nExclusion Criteria:\n\n* Type 1 Diabetes\n* Hepatic (liver) impairment\n* Renal (kidney) failure or dysfunction","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adjusted Mean Change in HbA1c Levels","description":"To assess the efficacy of dapagliflozin compared to placebo as add-on therapy to glimepiride in improving glycemic control in participants with type 2 diabetes, as determined by the change in HbA1C levels from baseline to the end of the 24-week double-blind treatment period.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.58","spread":null},{"groupId":"OG001","value":"-0.63","spread":null},{"groupId":"OG002","value":"-0.82","spread":null},{"groupId":"OG003","value":"-0.13","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Body Weight","description":"To show that dapagliflozin plus glimepiride results in greater reduction in body weight or less weight gain after 24 weeks of treatment when compared to placebo plus glimepiride.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.18","spread":null},{"groupId":"OG001","value":"-1.56","spread":null},{"groupId":"OG002","value":"-2.26","spread":null},{"groupId":"OG003","value":"-0.72","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in 2-h Post-challenge Plasma Glucose Rise","description":"To show that dapagliflozin plus glimepiride results in greater reductions in the 2-h post-challenge plasma glucose rise as a response to an oral glucose tolerance test (OGTT) from baseline to Week 24.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.5","spread":null},{"groupId":"OG001","value":"-32.0","spread":null},{"groupId":"OG002","value":"-34.9","spread":null},{"groupId":"OG003","value":"-6.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Participants Achieving Glycemic Response Defined as HbA1c <7%","description":"To show that dapagliflozin plus glimepiride results in a larger proportion of participants achieving a therapeutic glycemic response, defined as HbA1c \\< 7% after 24 weeks of treatment, compared to placebo plus glimepiride.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.8","spread":null},{"groupId":"OG001","value":"30.3","spread":null},{"groupId":"OG002","value":"31.7","spread":null},{"groupId":"OG003","value":"13.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Body Weight for Participants With Baseline Body Mass Index (BMI)≥27 kg/m2","description":"To show that dapagliflozin plus glimepiride results in greater reductions in body weight or less weight gain in participants with baseline BMI ≥27 kg/m2 after 24 weeks of treatment when compared to placebo plus glimepiride.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.17","spread":null},{"groupId":"OG001","value":"-1.74","spread":null},{"groupId":"OG002","value":"-2.47","spread":null},{"groupId":"OG003","value":"-0.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Adjusted Mean Change in Fasting Plasma Glucose (FPG)","description":"To show that dapagliflozin plus glimepiride leads to greater reductions in FPG after 24 weeks of treatment compared to placebo plus glimepiride.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.8","spread":null},{"groupId":"OG001","value":"-21.2","spread":null},{"groupId":"OG002","value":"-28.5","spread":null},{"groupId":"OG003","value":"-2.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":154},"commonTop":["Hypoglycemia","NASOPHARYNGITIS","HYPERTENSION"]}}}